Recall Issued for Blood Pressure Medicine Due to Potential Cancer Risk
In a recent development, Lupin Pharmaceuticals Inc. has issued a voluntary nationwide recall for four lots of Quinapril Tablets USP, 40 MG, due to the potential presence of N-Nitroso-Quinapril, a nitrosamine impurity, above the acceptable daily limit.
The affected lots are: - Lot No G100533 with an expiration date 12/2022 - Lot No G100534 with an expiration date 12/2022 - Lot No G203071 with an expiration date 03/2024
Patients taking the recalled medication are advised to contact their pharmacist, physician, or another medical provider for advice on an alternative treatment. The recalled lots should not be used and should be returned for reimbursement.
The FDA advises consumers to find more information about the UPC codes, label images, and other details by visiting the FDA's website. For reimbursement, the recalled lots should be returned to Inmar Rx Solutions, Inc.
Consumers, wholesalers, distributors, and retailers with questions regarding this recall should contact Inmar Rx Solutions, Inc. at (877) 538-8445.
Exposure to nitrosamines may increase the risk of cancer if levels are above acceptable limits over long periods of time. It is important to note that nitrosamines can be found in certain foods like cured and grilled meats, and dairy products, with cooking at high heat levels contributing to their presence.
This is not the first time a blood pressure drug has been recalled due to unacceptable levels of nitrosamines. In March 2022, Pfizer also performed a voluntary recall for similar medication. However, in our search up to August 2025, no specific recalls related to nitrosamines were explicitly mentioned for Lupin Pharmaceuticals Inc. or Pfizer.
The FDA's MedWatch Adverse Event Reporting program is available for reporting any adverse reactions or quality problems experienced with the use of this product.
This article is sourced from "Lupin Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Four Lots of Quinapril Tablets Due to Potential Presence of N-Nitroso-Quinapril Impurity" by the U.S. Food & Drug Administration.
For the most detailed and up-to-date specifics for Lupin Pharmaceuticals Inc. or Pfizer, consulting the FDA Enforcement Reports or official company announcements would be necessary. The FDA has been intensifying nitrosamine impurity testing, with many recalls affecting various manufacturers, but no direct mention of Lupin or Pfizer recalls due to nitrosamines was found in the latest public recalls listed.
Other medications recently recalled due to unacceptable levels of nitrosamines include Carvedilol 25 mg by Glenmark Pharmaceuticals, Doxepin Hydrochloride capsules, and Rizatriptan tablets (5 mg and 10 mg) by Ascend Laboratories.
Updates to FDA guidelines effective August 2025 require detection of over 250 nitrosamine compounds at very low levels, increasing scrutiny across the pharmaceutical industry and likely leading to further recalls or reformulations. Established acceptable intake limits for various nitrosamine impurities are tracked, but specific listed drugs affected by Lupin or Pfizer were not found in these results.
Science and health-and-wellness are relevant in this context as they relate to the potential health risks associated with the Quinapril Tablets recall due to the presence of the nitrosamine impurity, N-Nitroso-Quinapril. This recall underscores the importance of stringent testing and monitoring in pharmaceutical production as part of ongoing efforts to maintain public health and wellness, as guided by scientific research.
